190 related articles for article (PubMed ID: 35843374)
21. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
[TBL] [Abstract][Full Text] [Related]
22. Cause-specific mortality among patients with cirrhosis in a population-based cohort study in Ontario (2000-2017).
Wang PL; Djerboua M; Flemming JA
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37378630
[TBL] [Abstract][Full Text] [Related]
23. Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis.
D'Amico G; Abraldes JG; Rebora P; Valsecchi MG; Garcia-Tsao G
Hepatology; 2020 Sep; 72(3):1029-1042. PubMed ID: 31837238
[TBL] [Abstract][Full Text] [Related]
24. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
[TBL] [Abstract][Full Text] [Related]
25. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
26. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
27. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Brujats A; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J;
J Hepatol; 2021 Sep; 75(3):589-599. PubMed ID: 33905794
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
Duseja A; Singh SP; Mehta M; Shalimar ; Venkataraman J; Mehta V; Devadas K; Kar SK; Goyal O; Nagral A; Saigal S; Nijhawan S; Praharaj D; Shukla A; Sharma B; Narayanasamy K; Kumar P; Rao PN; Arora A; Mehta R; Asati P; Ranjan P; Koshy A; Alam S; Mukewar S; Mukewar S; Mohan Prasad VG; Rastogi M; Sanyal AJ
Metab Syndr Relat Disord; 2022 Apr; 20(3):166-173. PubMed ID: 35085026
[No Abstract] [Full Text] [Related]
29. Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease.
Ahmed HS; Pedersen N; Jayanna MB; Ten Eyck P; Sanchez A; Murali AR
J Gen Intern Med; 2020 May; 35(5):1523-1529. PubMed ID: 32157645
[TBL] [Abstract][Full Text] [Related]
30. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.
Henson JB; Simon TG; Kaplan A; Osganian S; Masia R; Corey KE
Aliment Pharmacol Ther; 2020 Apr; 51(7):728-736. PubMed ID: 32043602
[TBL] [Abstract][Full Text] [Related]
31. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
32. Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis.
Rivera-Esteban J; Manzano-Nuñez R; Broquetas T; Serra-Matamala I; Bassegoda O; Soriano-Varela A; Espín G; Castillo J; Bañares J; Carrión JA; Ginès P; Graupera I; Pericàs JM
JHEP Rep; 2022 Nov; 4(11):100574. PubMed ID: 36061511
[TBL] [Abstract][Full Text] [Related]
33. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
[TBL] [Abstract][Full Text] [Related]
34. Assessing the Risk of Further Decompensation and Survival in Patients With Cirrhosis With Variceal Bleeding as Their First Decompensation Event.
Gupta A; Rana R; Agarwal S; Sharma S; Gopi S; Mohta S; Gunjan D; Saraya A
Am J Gastroenterol; 2023 May; 118(5):833-839. PubMed ID: 36114777
[TBL] [Abstract][Full Text] [Related]
35. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
[TBL] [Abstract][Full Text] [Related]
36. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.
Rinella ME; Tacke F; Sanyal AJ; Anstee QM;
Hepatology; 2019 Oct; 70(4):1424-1436. PubMed ID: 31287572
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.
Haflidadottir S; Jonasson JG; Norland H; Einarsdottir SO; Kleiner DE; Lund SH; Björnsson ES
BMC Gastroenterol; 2014 Sep; 14():166. PubMed ID: 25260964
[TBL] [Abstract][Full Text] [Related]
38. Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis.
Sharpton SR; Oh TG; Madamba E; Wang C; Yu RT; Atkins AR; Huan T; Downes M; Evans RM; Loomba R
Aliment Pharmacol Ther; 2022 Nov; 56(10):1475-1485. PubMed ID: 36164267
[TBL] [Abstract][Full Text] [Related]
39. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
Petta S; Sebastiani G; Viganò M; Ampuero J; Wai-Sun Wong V; Boursier J; Berzigotti A; Bugianesi E; Fracanzani AL; Cammà C; Enea M; Grottes MD; Di Marco V; Younes R; Keyrouz A; Mazzola S; Mendoza Y; Pennisi G; Romero-Gomez M; Craxì A; de Ledinghen V
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):806-815.e5. PubMed ID: 32621970
[TBL] [Abstract][Full Text] [Related]
40. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
Vilar-Gomez E; Calzadilla-Bertot L; Wong VW; Castellanos M; Aller-de la Fuente R; Eslam M; Wong GL; George J; Romero-Gomez M; Adams LA
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):136-145.e6. PubMed ID: 32389886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
